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T-Lymphocyte Subset Studies to Monitor Patients with AIDS and 
AIDS-Related Complex 
Hajime Hayashi, PhD,* Eugene Mezger, MD,+ Michael J. Deegan, MD,* Evelyn J. 
Fisher, MD,* and Norman Markowitz, MD* 
Multiple specimens from 124 patients from our clinic were evaluated for T4IT8 cell ratio over three to 
28 months. Twenty-nine of 30patients with the acquired immunodeficiency syndrome (AIDS), 58 of 71 
patients with AIDS-related complex (ARC), and four of 23 patients at risk showed initial T4IT8 cell 
ratios of less than 0.8. which either remained unchanged or decreased. Seventeen of 23 AIDS patients 
and two of 20 ARC patients with a consistently low ratio (0.3 orless) died during the follow-up period. 
This indicated that the severity of disease could be predicted by periodical T4IT8 cell ratio studies. 
These serial studies appeared to be valuable in monitoring the course of patients with AIDS, ARC, and 
the human immunodeficiency virus infection and also in evaluating the effects of available drug 
treatments. (Henry Ford Hosp Med J 1987:35:30-2) 
The most commonly used laboratory tests for evaluating pa-tients with the acquired immunodeficiency syndrome 
(AIDS) are the anti-human immunodeficiency vims (anti-HlV) 
antibody test (1) and the subpopulation study of T-lymphocytes 
(helper/suppressor or T4/T8 cell ratio) (2), [Naming of the 
human immunodeficiency virus (HIV) for lymphadenopathy-
associated vims (LAV), human T-cell lymphotropic vims type 
III (HTLV-III), immunodeficiency-associated virus (IDAV), 
and AIDS-associated retrovirus (ARV) was proposed by the 
subcommittee and endorsed by the executive committee of the 
Intemational Committee on the Taxonomy of Vimses (3).] Since 
the etiological agent of AIDS was established (4-6), the anti-
HIV test has been used at blood donor stations to screen for the 
HIV-infected donor (7,8). It is also used at clinics as a diagnostic 
tool for patients with AIDS or AIDS-related complex (ARC). 
This serologic test can detect the antibody which indicates past 
or present infection with HIV, This test, however, is of limited 
value in the follow-up or prognosis of disease, because when a 
patient tests positive, the antibody usually stays positive there-
after. The relationship of antibody levels to the course of disease 
is not established. 
Serial study of T4/T8 cell ratio is useful for monitoring the 
immunological status of a given patient over time. We are re-
porting an application of the T4/T8 cell ratio in the prognosis of 
patients with AIDS and ARC. 
Clinical Specimens 
For purposes of clinical classification, the following criteria 
were adopted. The definition of AIDS was based on criteria from 
the Centers for Disease Control (9). ARC was defined to include 
those patients who were anti-HIV antibody positive by both en-
zyme immunoassay (1) and Westem blot technique (10) and who 
did not have AIDS but displayed the symptoms, signs, or labora-
tory abnormalities consistent with HIV infections. At-risk 
patients were HIV antibody positive without clinical manifesta-
tions of disease. 
The 124 patients studied were classified into three groups: 
1) 30 AIDS patients, 2) 71 ARC patients, and 3) 23 at-risk pa-
tients. Blood specimens from these patients were evaluated over 
three to 28 months (average 8.7 months). 
Methods 
Testing for anti-HIV antibody 
Antibody to HIV was measured with the Abbott HTLV-III en-
zyme immunoassay (Abbott Laboratories, North Chicago, IL) 
(1). Reactive semm specimens were tested by the Westem blot 
technique for confirmation (10). 
Testing for T-lymphocyte subset 
T-lymphocyte subset study was performed by direct immu-
nofluorescence on a flow cytometer (Coulter EPICS V) with use 
of commercially available monoclonal antibodies (OKTll for 
total T, OKT4 for T-helper, and 0KT8 for T-suppressor cells 
from Ortho Pharmaceuticals, Raritan, NJ) (11). The buffy coat 
from heparinized blood was first reacted with each monoclonal 
antibody conjugated with fluorescence isothiocyanate for 
30 minutes in an ice bath. After eliminating erythrocytes by 
a lysing reagent, tagged cells were fixed with 0.5% para-
formaldehyde before testing. The percent of positive cells for 
each subset was measured on "gated" lymphocytes by flow 
cytometer The absolute count ofeach T-cell population was also 
calculated. 
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Results 
The normal ranges of T-lymphocyte subpopulations estab-
lished from 84 "normal" individuals at our laboratory are 
summarized in Table I . A T4/T8 cell ratio lower than 0.8 was 
considered "low" and 0,3 or less "extremely low." 
Table 2 summarizes a comparison of T4/T8 cell ratio and anti-
HIV antibody in 124 patients (30 AIDS patients, 71 ARC pa-
tients, and 23 at-risk patients). The HI V-antibody test detected 
exposure to the vims. When patients tested positive, they usu-
ally stayed positive thereafter, regardless of the clinical course. 
On the other hand, the T4/T8 cell ratio can stratify the patients 
by a low (0.4 to 0.7) or extremely low (0.3 or less) ratio. These 
values were subsequently shown to be related to the clinical 
course. 
Table 3 shows the follow-up study of these patients by T4/T8 
cell ratio. A total of 377 specimens from 124 patients were sub-
mitted (average 3.0 specimens per patient). The T4/T8 cell ratio 
in those patients with low and extremely low ratios did not 
change. However, some patients who had an initially normal 
ratio fell to low or extremely low ratios during the follow-up 
period. One AIDS patient, nine ARC patients, and six at-risk 
patients demonstrated a reversal of T4/T8 cell ratios on subse-
quent specimens. None of the patients improved the ratio on the 
subsequent specimens. Seventeen of 23 AIDS patients and two 
of 20 ARC patients with a consistently low ratio (0.3 or less) 
died during the follow-up period. This indicated that the severity 
of disease could be predicted by an extremely low T4/T8 cell 
ratio. 
The follow-up data for two patients are shown in Table 4 as 
examples. Decrease of the absolute count of T-lymphocytes was 
also evident with extremely low cell ratios, although the two 
were not always associated. 
Discussion 
Enzyme immunoassay for anti-HIV antibody is a simple test 
to detect a patient's exposure to the virus and is sensitive for 
screening at-risk patients. The T-lymphocyte subset study 
reveals the degree of suppression in T-lymphocytes. 
The simultaneous anti-HIV antibody and T4/T8 cell ratio as-
says are most helpful for the stratification of patients with AIDS 
or ARC. These patients were found to have low or extremely low 
T4/T8 cell ratios. The patients with extremely low ratios had a 
poor prognosis. Patients with HIV antibody and normal T4/T8 
cell ratios were usually in the asymptomatic at-risk group. 
Serial testing of the T4/T8 cell ratio is useful in monitoring 
the changing immunological status of the following groups: 
1) parients with ARC (not full-blown AIDS); 2) individuals 
at risk (anti-HIV antibody positive by routine screening, but 
without symptoms); and 3) patients with HIV under antiviral 
therapy. 
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Table 1 
Normal Ranges for T-Lymphocyte Subpopulations (n = 84) 
Mean '/< 
Standard 
Deviation Normal % 
Ranges 
Mean ± Standard Deviation 
(absolute count) 
T i l (total) 72.3 7.2 57.3-86.7 (530-27 lO/mm') 
T4 (helper) 49.5 8.1 33.4-65.6 (400-1730/mmi) 
T8 (sup-
pressor) 26.8 6.9 13.1-40.6 (150-990/mm3) 
T4/T8 cell 
ratio 2.0 0.6 0.8-3.2 
Table 2 
Comparison of Helper (T4) and Suppressor (T8) 
T-Lymphocyte Ratio and Anti-HIV Antibody in Three 
Patient Groups 
T4/T8 Cell 
Ratio 
Number of Patients (Anti-HIV Antibody Positive) 
AIDS ARC At Risk 
Normal: s= 0.8 1 (1) 13 (7) 19(6) 
Low: 0.4-0.7 6 (4) 38(35) 4(2) 
Extremely low: 0.3 23 (23) 20(18) 0 
Total: 124 patients 30 (28) 71 (60) 23 (8) 
Table 3 
Follow-up Study of Helper (T4) and Suppressor (T8) 
T-Lymphocyte Ratio in Three Patient Groups 
T4/T8 Cell Ratio Number of Patients (Deceased) 
Initial Subsequent Change AIDS ARC At Risk 
3= 0.8 No change 0 4 13 
i 1 9 6 
0.4-0.8 No change 3 31 4 
t o r i 3 7 0 
=s 0.3 23 (17) 20(2) 0 
Total: 124 30 (17) 71 (2) 23 
i = decreased. 
t or I = fluctuated within abnormal range. 
Table 4 
Follow-up Study 
TH 
T-Lymphocyte Subset 
T4 T8 T4/T8 
Example 1: Patient with AIDS* 
1st specimen 81% 40% 47% 0.85 
(I318)t (640) (753) 
6 months 74% 9% 58% 0.15 
(783) (95) (614) 
10 months 64% 8% 50% 0.16 
(922) (50) (720) 
Example 2: Patient with ARC* 
1 st specimen 57% 3% 59% 0.05 
(629) (33) (658) 
8 months 84% 1% 66% 0.02 
(428) (5) (337) 
8 months (deceased) 
*Both patients were anti-HIV positive. 
tAbsolute count. 
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